InvestorsObserver

ANL Adlai Nortye Ltd.

$13.00 $-0.05 (-0.38%)
15 Minute Delayed Price Enable Real-Time Price
Overall NA

ANL Stock Analysis Overview

No Overall Rank data available for Adlai Nortye Ltd. (ANL)

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ANL Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ANL Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ANL Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ANL Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ANL Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ANL Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ANL Stock Analysis Overview

No Overall Rank data available for Adlai Nortye Ltd. (ANL)

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ANL report

ANL Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ANL Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ANL Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ANL Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ANL Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ANL Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Adlai Nortye Ltd. (ANL) Analyst Forecast

ANL Price, Volume, Earnings, and Dividend Date

  • Last Price $13.00
  • Previous Close $13.05
  • Change $-0.05
  • Open $12.61
  • Volume 4,026
  • Avg. Volume (100-day) 5,518
  • Market Cap 479,703,484
  • Days Range 11.7881 - 13.25
  • 52-week Range 7.11 - 19.3
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date
  • Sector
  • Industry
  • Avg. Analyst Rec. Premium
  • Beta
  • PEG Ratio

Adlai Nortye Ltd. (ANL) Company Description

Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company¿s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.

Adlai Nortye Ltd. (ANL) Stock Chart